Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan as adjunctive therapy to inhaled nitric oxide for persistent pulmonary hypertension of the newborn
2011-000203-41Phase 3Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in persistent pulmonary hypertension of the newborn (PPHN) comparing Bosentan + inhaled nitric oxide with Placebo + inhaled nitric oxide (2 arms). Primary endpoint: Treatment failure. Started Jul 2011; status: terminated.
02
Drugs
bosentan
03
Conditions
persistent pulmonary hypertension of the newborn (PPHN)
Beyond the preview
Go deeper on 2011-000203-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000203-41.